This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

II. Initial Therapy in 33 Neurologically Affected Patients and Follow-up With Zinc Therapy

George J. Brewer, MD; Virginia Johnson, MS; Robert D. Dick; Karen J. Kluin, MS; John K. Fink, MD; James A. Brunberg, MD

Arch Neurol. 1996;53(10):1017-1025.

Abstract
Objective
To test the efficacy and toxic effects of ammonium tetrathiomolybdate in the initial treatment of a relatively large series of patients with neurologic symptoms and signs caused by Wilson disease. Two key aspects of efficacy are to preserve the neurologic function present at the onset of therapy and to maximize the opportunity for long-term recovery.

Design
An open study of 33 patients treated for 8 weeks each, including further follow-up data on the original 17 patients. Neurologic function was evaluated by frequent quantitative neurologic and speech pathology examinations. Several copper-related variables were studied to evaluate the effect of the drug on copper, and several biochemical and clinical variables were studied to evaluate potential toxic effects. Patients were then followed up at yearly intervals, with follow-up periods of 1 to 8 years reported.

Setting
A university hospital referral setting.

Intervention
Patients were generally treated for 8 weeks with tetrathiomolybdate, followed by zinc maintenance therapy.

Main Outcome Measures
Neurologic function was evaluated by quantitative neurologic and motor speech examinations and magnetic resonance imaging scans of the brain.

Results
During the 8 weeks of tetrathiomolybdate administration, only 1 of the 33 patients showed deterioration in neurologic function. Copper status and potential further toxic effects were generally well controlled quickly. Evaluation of data from individual patients revealed evidence of a toxic side effect in only 1 patient, who exhibited reversible anemia. During the ensuing period of follow-up of 1 to 6 years, neurologic recovery in most patients was good to excellent.

Conclusions
Tetrathiomolybdate appears to be an excellent form of initial treatment in patients with Wilson disease who present with neurologic symptoms and signs. In contrast to penicillamine therapy, initial treatment with tetrathiomolybdate rarely allows further, often irreversible, neurologic deterioration.

Author Affiliations
From the Departments of Human Genetics (Dr Brewer, Ms Johnson, and Mr Dick), Internal Medicine (Dr Brewer), the Division of Speech-Language Pathology, Department of Physical Medicine and Rehabilitation (Ms Kluin), and the Departments of Neurology (Ms Kluin and Drs Fink and Brunberg) and Radiology (Dr Brunberg), University of Michigan Medical School, Ann Arbor.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Improvement in Dissolution of Liver Fibrosis in an Animal Model by Tetrathiomolybdate
Hou et al.
Exp. Biol. Med. 2009;234:662-665.
ABSTRACT | FULL TEXT  

Tetrathiomolybdate Is Partially Protective Against Hyperglycemia in Rodent Models of Diabetes
Zeng et al.
Exp. Biol. Med. 2008;233:1021-1025.
ABSTRACT | FULL TEXT  

Function and Regulation of Human Copper-Transporting ATPases
Lutsenko et al.
Physiol. Rev. 2007;87:1011-1046.
ABSTRACT | FULL TEXT  

Treatment of Wilson Disease With Ammonium Tetrathiomolybdate: IV. Comparison of Tetrathiomolybdate and Trientine in a Double-blind Study of Treatment of the Neurologic Presentation of Wilson Disease.
Brewer et al.
Arch Neurol 2006;63:521-527.
ABSTRACT | FULL TEXT  

Combination tetrathiomolybdate and radiation therapy in a mouse model of head and neck squamous cell carcinoma.
Khan et al.
Arch Otolaryngol Head Neck Surg 2006;132:333-338.
ABSTRACT | FULL TEXT  

Phase II Trial of Tetrathiomolybdate in Patients with Advanced Kidney Cancer
Redman et al.
Clin. Cancer Res. 2003;9:1666-1672.
ABSTRACT | FULL TEXT  

Soy Protein Isolate Enhances Hepatic Copper Accumulation and Cell Damage in LEC Rats
Yonezawa et al.
J. Nutr. 2003;133:1250-1254.
ABSTRACT | FULL TEXT  

Treatment of Wilson Disease With Ammonium Tetrathiomolybdate: III. Initial Therapy in a Total of 55 Neurologically Affected Patients and Follow-up With Zinc Therapy
Brewer et al.
Arch Neurol 2003;60:379-385.
ABSTRACT | FULL TEXT  

Cancer Therapy With Tetrathiomolybdate: Antiangiogenesis by Lowering Body Copper--A Review
Brewer and Merajver
Integr Cancer Ther 2002;1:327-337.
ABSTRACT  

Copper Control as an Antiangiogenic Anticancer Therapy: Lessons from Treating Wilson's Disease
Brewer
Exp. Biol. Med. 2001;226:665-673.
ABSTRACT | FULL TEXT  

Wilson's disease with severe hepatic insufficiency: beneficial effects of early administration of D-penicillamine
Durand et al.
Gut 2001;48:849-852.
ABSTRACT | FULL TEXT  

Recognition, Diagnosis, and Management of Wilson's Disease
Brewer
Exp. Biol. Med. 2000;223:39-46.
ABSTRACT | FULL TEXT  

Treatment of Metastatic Cancer with Tetrathiomolybdate, an Anticopper, Antiangiogenic Agent: Phase I Study
Brewer et al.
Clin. Cancer Res. 2000;6:1-10.
ABSTRACT | FULL TEXT  

A homesick student
McDonnell and Esmonde
Postgrad. Med. J. 1999;75:375-378.
FULL TEXT  

Recent advances: Hepatology
McCarthy and Wilkinson
BMJ 1999;318:1256-1259.
FULL TEXT  

Neuropsychiatric Correlates and Treatment of Lenticulostriatal Diseases: A Review of the Literature and Overview of Research Opportunities in Huntington's, Wilson's, and Fahr's Diseases
ANPA Committee on Research et al.
J. Neuropsychiatry Clin. Neurosi. 1998;10:249-266.
ABSTRACT | FULL TEXT  

Copper Induces the Assembly of a Multiprotein Aggregate Implicated in the Release of Fibroblast Growth Factor 1 in Response to Stress
Landriscina et al.
J. Biol. Chem. 2001;276:25549-25557.
ABSTRACT | FULL TEXT